国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
2期
193-196
,共4页
舒利迭%慢性阻塞性肺疾病%肺气肿%中性粒细胞弹性蛋白酶%α1-抗胰蛋白酶
舒利迭%慢性阻塞性肺疾病%肺氣腫%中性粒細胞彈性蛋白酶%α1-抗胰蛋白酶
서리질%만성조새성폐질병%폐기종%중성립세포탄성단백매%α1-항이단백매
Seretide%Chronic obstructive pulmonary disease%Pulmonary emphysema%Neutrophil elastase%α1-antitrypsin
目的 探讨吸入舒利迭(沙美特罗替卡松粉吸入剂)对COPD(慢性阻塞性肺疾病)肺气肿患者血清NE、α 1-AT的影响,为临床COPD肺气肿治疗提供依据.方法 选择COPD肺气肿患者142例,按照COPD严重程度进行分型,轻度75例,中度42例,重度25例,所有患者均采用舒利迭治疗,另选30例健康体检者作对照组,观察三组患者治疗前后血清NE、α 1-AT的变化情况,并与对照组比较;观察患者肺气肿、肺功能恢复情况.结果 治疗前不同严重程度患者的α1-AT较健康对照组明显降低(P＜0.05),病情越严重,α1-AT水平越低(P＜0.05),而NE水平则较健康对照组明显增高,随病情严重度增加而增加(P＜0.05);治疗后轻度COPD患者α1-AT明显增,NE则明显下降(P＜0.05);中度、重度COPD患者α1-AT及NE改善不明显或无改善(P＞0.05);轻度组患者肺气肿恢复率、肺功能改善明显高于中、重度患者(P＜ 0.05).结论 舒利迭治疗COPD肺气肿,对病情较轻的患者可有效改善NE、α1-AT水平,使蛋白酶/抗蛋白酶趋于平衡,但对于中度、重度的患者的效果甚微.
目的 探討吸入舒利迭(沙美特囉替卡鬆粉吸入劑)對COPD(慢性阻塞性肺疾病)肺氣腫患者血清NE、α 1-AT的影響,為臨床COPD肺氣腫治療提供依據.方法 選擇COPD肺氣腫患者142例,按照COPD嚴重程度進行分型,輕度75例,中度42例,重度25例,所有患者均採用舒利迭治療,另選30例健康體檢者作對照組,觀察三組患者治療前後血清NE、α 1-AT的變化情況,併與對照組比較;觀察患者肺氣腫、肺功能恢複情況.結果 治療前不同嚴重程度患者的α1-AT較健康對照組明顯降低(P＜0.05),病情越嚴重,α1-AT水平越低(P＜0.05),而NE水平則較健康對照組明顯增高,隨病情嚴重度增加而增加(P＜0.05);治療後輕度COPD患者α1-AT明顯增,NE則明顯下降(P＜0.05);中度、重度COPD患者α1-AT及NE改善不明顯或無改善(P＞0.05);輕度組患者肺氣腫恢複率、肺功能改善明顯高于中、重度患者(P＜ 0.05).結論 舒利迭治療COPD肺氣腫,對病情較輕的患者可有效改善NE、α1-AT水平,使蛋白酶/抗蛋白酶趨于平衡,但對于中度、重度的患者的效果甚微.
목적 탐토흡입서리질(사미특라체잡송분흡입제)대COPD(만성조새성폐질병)폐기종환자혈청NE、α 1-AT적영향,위림상COPD폐기종치료제공의거.방법 선택COPD폐기종환자142례,안조COPD엄중정도진행분형,경도75례,중도42례,중도25례,소유환자균채용서리질치료,령선30례건강체검자작대조조,관찰삼조환자치료전후혈청NE、α 1-AT적변화정황,병여대조조비교;관찰환자폐기종、폐공능회복정황.결과 치료전불동엄중정도환자적α1-AT교건강대조조명현강저(P＜0.05),병정월엄중,α1-AT수평월저(P＜0.05),이NE수평칙교건강대조조명현증고,수병정엄중도증가이증가(P＜0.05);치료후경도COPD환자α1-AT명현증,NE칙명현하강(P＜0.05);중도、중도COPD환자α1-AT급NE개선불명현혹무개선(P＞0.05);경도조환자폐기종회복솔、폐공능개선명현고우중、중도환자(P＜ 0.05).결론 서리질치료COPD폐기종,대병정교경적환자가유효개선NE、α1-AT수평,사단백매/항단백매추우평형,단대우중도、중도적환자적효과심미.
Objective To investigate the effect of inhaled seretide in serum NE,α1-AT of COPD patients with emphysema,in order to provide basis for clinically treating emphysema.Methods 142 COPD patients with emphysema were selected and parted according to severity of COPD (75 mild cases,42 moderate cases and 25 severe cases),who were all treated with seretide.30 healthy people were selected as control group.Serum NE,α1-AT levels of three groups of patients before and after treatment and control group,emphysema and lung function recovery of patients were observed.Results Before treatment,α1-AT level of patients was lower than that of control group(P ＜ 0.05); the more serious illness was,the lower α1-AT level was (P ＜ 0.05).NE level of patients was significantly higher than that of control group; the more serious illness was,the higher NE level was (P ＜ 0.05).After treatment,α1-AT level of mild patients significantly increased,but NE level significantly decreased (P ＜ 0.05); α1-AT levels of moderate and severe patients didn' t significantly change (P ＞ 0.05).The emphysema recovery rate and lung function of mild patients improved more than those of moderate and severe patients (P ＜ 0.05).Conclusions Inhaled seretide in the treatment of COPD with emphysema can effectively improve NE and α1-AT level of mild patients,make protease/antiprotease balanced,but has little effect on moderate and severe patients.
